Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

EVALUATING CLINICAL BENEFIT IN SARCOMAS

Award Number: R13CA113090
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/23/2004
PERIOD OF PERFORMANCE END DATE: 08/31/2005

Group Awards By:

View Award Description

EVALUATING CLINICAL BENEFIT IN SARCOMAS - DESCRIPTION (provided by applicant): SARC (Sarcoma Alliance for Research through Collaboration) is a consortium of oncologists who collaborate on research endeavors and will be the sponsor of this symposium. SARC is registered in the state of Michigan as a 501.c.3 non-profit organization. It is organized as a directorship. The board of directors includes Laurence H. Baker, DO (University of Michigan Cancer Center) Executive Director, Robert Benjamin, MD (MD Anderson Cancer Center) Vice-President, Lee Helman, MD (NCI-Pediatric Branch) Secretary and Robert Maki, MD, PhD, (Memorial Sloan Kettering Cancer Center) Treasurer. SARC facilitates dialogue and collaboration among sarcoma researchers and clinicians, assists in the development and dissemination of protocols for clinical trials and information relating to sarcoma research and the results of clinical trials, administers research grants and funding for clinical trials, and acts as a primary resource for those treating sarcoma. Sponsoring of the planned scientific symposium fits well with the mission and goals of SARC. The symposium, Evaluating Clinical Benefit in Sarcomas, will be held November 11, 2004 as part of the international meeting of the Connective Tissue Oncology Society in Montreal, Quebec. The purpose of this symposium is to review imaging studies to evaluate patients with sarcoma, compare and contrast response to therapy as evaluated by RECIST criteria vs. newer approaches including functional imaging with CT and/or MRI and PET, and to determine if alternate criteria either functional or anatomic provide clinical advantage versus RECIST. While the focus of this conference is sarcomas, these discussions are appropriate to other solid tumors. Speakers will be radiologists and medical oncologists. The intended audience is the FDA, the NCI and oncologists. The ultimate goal is to publish the proceedings of this meeting.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2004 ( Subtotal = $8,500 )
2004	2004	SARC INC	110 MILLER	ANN ARBOR	MI	48104	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	1	9/23/2004	NEW	$8,500
														Subtotal = $8,500

Grand Total All Awards = $8,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

EVALUATING CLINICAL BENEFIT IN SARCOMAS

Award Number: R13CA113090

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/23/2004

PERIOD OF PERFORMANCE END DATE: 08/31/2005

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer